Advertisement
New Zealand markets close in 3 hours 11 minutes
  • NZX 50

    11,739.63
    +23.19 (+0.20%)
     
  • NZD/USD

    0.6119
    -0.0003 (-0.06%)
     
  • NZD/EUR

    0.5707
    -0.0002 (-0.03%)
     
  • ALL ORDS

    8,035.70
    -41.20 (-0.51%)
     
  • ASX 200

    7,798.10
    -40.70 (-0.52%)
     
  • OIL

    80.92
    +0.09 (+0.11%)
     
  • GOLD

    2,326.00
    -4.80 (-0.21%)
     
  • NASDAQ

    19,701.13
    +226.51 (+1.16%)
     
  • FTSE

    8,247.79
    -33.76 (-0.41%)
     
  • Dow Jones

    39,112.16
    -299.05 (-0.76%)
     
  • DAX

    18,177.62
    -147.96 (-0.81%)
     
  • Hang Seng

    17,970.53
    -102.37 (-0.57%)
     
  • NIKKEI 225

    39,534.85
    +361.70 (+0.92%)
     
  • NZD/JPY

    97.7090
    +0.0580 (+0.06%)
     

Revvity to Present at Goldman Sachs Global Healthcare Conference

WALTHAM, Mass., May 28, 2024--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the 45th Annual Goldman Sachs Global Healthcare Conference on Monday, June 10, 2024 at 8:00 a.m. ET in Miami, FL.

Prahlad Singh, president and chief executive officer, will provide an update on the Company and its strategic priorities. To register, click here.

A live audio webcast will be available on the Events section of the Company’s website at www.revvity.com. A replay of the presentation will be posted on the Revvity Investor Relations website after the event and will be available for at least 30 days.

About Revvity

At Revvity, "impossible" is inspiration, and "can’t be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

ADVERTISEMENT

With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240528846410/en/

Contacts

Investor Relations:
Steve Willoughby
steve.willoughby@revvity.com

Media Relations:
Chet Murray
(781) 663-5719
chet.murray@revvity.com